|
|
|
Molecular Insight Pharmaceuticals, Inc. to Present Data on Four Oncology Candidates at Society of Nuclear Medicine 2008 Annual Meeting
- Eight Presentations to Highlight Company’s Robust Oncology Portfolio -
Cambridge, MA, May 20, 2008 – Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI) announced today that it will present study results on four of its oncology candidates at the 55th annual meeting of the Society of Nuclear Medicine (SNM). The meeting will take place June 14 -18, 2008 in New Orleans, LA. Presentations will include data on Azedra™ (Ultratrace™ 131I-MIBG), the company’s targeted radiotherapeutic candidate for the treatment of neuroendocrine tumors; Trofex™, its molecular imaging radiopharmaceutical candidate for the detection and monitoring of prostate cancer; Onalta™, a targeted radiotherapeutic complementary to Azedra that is in development for the treatment of neuroendocrine tumors such as carcinoid; and Solazed™, a targeted radiotherapeutic in development for the treatment of metastatic melanoma. The abstract and presentation details are as follows:
| Abstract Title: |
Molecular targeting of melanoma with radiolabeled benzamides |
| Authors: |
J. L. Joyal*1, S. M. Hillier1, J. C. Marquis1, J. Chen1, M. Friebe2, J. A. Barrett1, J. F. Kronauge1 and J. W. Babich1; 1. Discovery Research, Molecular Insight Pharmaceuticals, Inc., Cambridge, Massachusetts and 2. Molecular Imaging Research, Bayer Healthcare, Berlin, Germany |
| Reference #: |
456331 |
| Publication No.: |
61 - Scientific Paper Session (oral) |
| Session Info: |
Basic Science: Therapeutic Approaches
Sunday, June 15
12:45 PM - 2:15 PM
Room 225-226
|
| Abstract Title: |
Comparative analysis of 111In-edotreotide, 90Y-edotreotide and 111In-pentetreotide in vivo and in vitro |
| Authors: |
J. C. Marquis*1, S. M. Hillier1, T. Besanger1, J. F. Kronauge1, J. A. Barrett1, T. L. Anderson2, D. J. Irwin2, J. P. Norenberg2, J. L. Joyal1 and J. W. Babich1; 1. Molecular Insight Pharmaceuticals, Inc., Cambridge, Massachusetts and 2. University of New Mexico Health Sciences Center, College of Pharmacy, Albuquerque, New Mexico |
| Reference #: |
461899 |
| Publication No.: |
63 - Scientific Paper Session (oral) |
| Session Info: |
Basic Science: Therapeutic Approaches
Sunday, June 15
12:45 PM - 2:15 PM
Room 225-226 |
| Abstract Title: |
A novel infusion method for therapeutic radiopharmaceuticals |
| Authors: |
D. L. Yokell*1, S. C. Dragotakes2, P. W. Gallagher3, M. de la Guardia1, J. F. Kronauge1, J. P. Norenberg4, N. A. Petry5, J. A. Ponto6 and J. W. Babich1; 1. Molecular Insight Pharmaceuticals, Inc., Cambridge, Massachusetts; 2. Massachusetts General Hospital, Boston, Massachusetts; 3. Brigham and Women’s Hospital, Boston, Massachusetts; 4. University of New Mexico, Albuquerque, New Mexico; 5. Duke University Medical Center, Durham, North Carolina and 6. University of Iowa Hospitals and Clinics, Iowa City, Iowa |
| Reference #: |
461312 |
| Publication No.: |
1298 - Scientific Poster Session |
| Poster Section: |
Radiopharmacy Posters |
| Session Info: |
Meet the Author II
Monday, June 16
3:15 PM - 4:00 PM
Exhibit Hall B2 |
| Abstract Title: |
The development of an SAR with small molecule inhibitors of prostate specific membrane antigen (PSMA) |
| Authors: |
K. P. Maresca*, S. M. Hillier, F. J. Femia, C. Barone, D. Keith, J. L. Joyal, C. N. Zimmerman, J. A. Barrett, W. C. Eckelman and J. W. Babich; Molecular Insight Pharmaceuticals, Inc., Cambridge, Massachusetts |
| Reference #: |
455192 |
| Publication No.: |
1236 - Scientific Poster Session |
| Poster Section: |
New Chemistry-Oncology Posters |
| Session Info: |
Meet the Author II
Monday, June 16
3:15 PM - 4:00 PM
Exhibit Hall B2 |
| Abstract Title: |
Ongoing phase I evaluation of MTD, safety and efficacy of Iobenguane I 131 in malignant pheochromocytoma and paraganglioma (Pheo) |
| Authors: |
R. Coleman*1, M. A. Morse1, N. LaFrance2, K. A. Kacena2 and J. W. Babich2; 1. Radiology, Duke University Medical Center, Durham, North Carolina and 2. Molecular Insight Pharmaceuticals, Inc., Cambridge, Massachusetts |
| Reference #: |
463712 |
| Publication No.: |
402 - Scientific Paper Session (oral) |
| Session Info: |
TMI: Clinical Radionuclide Therapy
Tuesday, June 17
9:45 AM - 11:15 AM
Room 225-226 |
| Abstract Title: |
[123I]-MIP-1095 for targeting prostate cancer via prostate specific membrane antigen (PSMA): A high specific activity radiosynthesis |
| Authors: |
F. J. Femia*, K. P. Maresca, S. M. Hillier, J. C. Marquis, E. Luss-Lusis, C. N. Zimmerman, J. L. Joyal, B. Abeysekera, J. F. Kronauge and J. W. Babich; Molecular Insight Pharmaceuticals, Inc., Cambridge, Massachusetts |
| Reference #: |
449940 |
| Publication No.: |
393 - Scientific Paper Session (oral) |
| Session Info: |
New Chemistry-Oncology II: Small Molecules
Tuesday, June 17
2:30 PM - 4:00 PM
Room 215-216 |
| Abstract Title: |
Small molecule PSMA inhibitors for targeted molecular imaging of prostate cancer |
| Authors: |
S. M. Hillier*1, K. P. Maresca1, F. J. Femia1, C. N. Zimmerman1, J. A. Barrett1, C. A. Foss2, W. C. Eckelman1, M. G. Pomper2, J. L. Joyal1 and J. W. Babich1; 1. Molecular Insight Pharmaceuticals, Inc., Cambridge, Massachusetts and 2. Johns Hopkins Medical Institutions, Baltimore, Maryland |
| Reference #: |
453735 |
| Publication No.: |
389 - Scientific Paper Session (oral) |
| Session Info: |
New Chemistry-Oncology II: Small Molecules
Tuesday, June 17
2:30 PM - 4:00 PM
Room 215-216 |
| Abstract Title: |
Determination of the ability of 111In Onalta (edotreotide) to be used as an imaging surrogate for the accurate prediction of 90Y Onalta radiation absorbed dose |
| Authors: |
J. A. Barrett*1, T. Anderson2, S. Hillier1, D. Irwin2, J. P. Norenberg2, J. B. Stubbs3, M. G. Stabin3, J. L. Joyal1, K. Kacena1 and J. W. Babich1; 1. research, Molecular Insight Pharmaceuticals, Inc., Cambridge, Massachusetts; 2. College of Pharmacy, University of New Mexico, Albuquerque, New Mexico and 3. Radiation Dosimetry Systems, Palo Alto, California |
| Reference #: |
456518 |
| Publication No.: |
1411 - Scientific Poster Session |
| Poster Section: |
Therapy, Metrics & Intervention Posters |
| Session Info: |
Meet the Author III
Tuesday, June 17
4:30 PM - 5:15 PM
Exhibit Hall B2 |
About Molecular Insight Pharmaceuticals, Inc.
Molecular Insight Pharmaceuticals (NASDAQ: MIPI) is a biopharmaceutical company specializing in the emerging field of molecular medicine, applying innovations in the identification and targeting of disease at the molecular level to improve healthcare for patients with life-threatening diseases. The company is focused on discovering, developing and commercializing innovative, molecular radiotherapeutics and molecular imaging pharmaceuticals with initial applications in the areas of oncology and cardiology. Its lead molecular radiotherapeutic product candidates, Azedra and Onalta, are being developed for detection and treatment of cancer. The company's lead molecular imaging pharmaceutical product candidate, Zemiva, is being developed for the diagnosis of cardiac ischemia, or insufficient blood flow to the heart. In addition, the company has a growing pipeline of product candidates resulting from application of its proprietary platform technologies to new and existing compounds. Molecular Insight Pharmaceuticals is based in Cambridge, Massachusetts and its website address is: www.molecularinsight.com.
Forward-Looking Statements
Statements in this release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, statements about the development of AzedraTM, OnaltaTM, ZemivaTM and our other product candidates. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause the actual results of Molecular Insight to be materially different from historical results or from any results expressed or implied by such forward-looking statements. These factors include, but are not limited to, risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval for product candidates; competition from other pharmaceutical or biotechnology companies; and the additional risks discussed in filings with the Securities and Exchange Commission. All forward-looking statements are qualified in their entirety by this cautionary statement, and Molecular Insight undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof.
Contact:
Priscilla Harlan
Vice President, Corporate Communications
Molecular Insight Pharmaceuticals, Inc.
(617) 492-5554
Print Top ^
|
|